Confronti finanziari Novartis AG

Azioni

Mercato chiuso - Swiss Exchange Altri mercati azionari 17:31:52 16/01/2026			Variaz. 5gg	Var. 1 gen.
115,60 ^CHF	+0,98%		+1,37%	+5,47%

16/01	Novartis: Ianalumab ottiene la designazione di Breakthrough Therapy dalla FDA per la malattia di Sjögren	CI
16/01	Novartis ottiene la designazione di terapia rivoluzionaria dalla FDA statunitense per Ianalumab nel trattamento della malattia di Sjögren	MT

Settore:

Regione:

Asse X:

Principali concorrenti

Aggiungi a un elenco 0 selezionato Solo clienti o iscritti possono usare questa funzione Accedi Registrati	Fatturato (Y-1)	Margine netto (Y-1)	Margine EBIT (Y-1)	ROE (Y-1)	ROA (Y-1)	Leverage (Y-1)
NOVARTIS AG	51,72 Mrd	23,08%	37,69%	34,74%	15,58%	0.85x
ELI LILLY AND COMPANY	45,04 Mrd	23,51%	31,78%	84,84%	14,84%	1.88x
JOHNSON & JOHNSON	88,82 Mrd	15,84%	29,8%	34,23%	13,95%	0.41x
ABBVIE INC.	56,33 Mrd	7,59%	41,43%	263,08%	13,34%	2.56x
ROCHE HOLDING AG	66,76 Mrd	13,68%	34,42%	43,45%	15,69%	0.74x
ASTRAZENECA PLC	54,07 Mrd	13,01%	31,31%	32,11%	12,51%	1.47x
MERCK & CO., INC.	64,17 Mrd	26,68%	36,46%	46,35%	17,38%	0.86x
NOVO NORDISK A/S	40,31 Mrd	34,78%	44,19%	80,78%	25,88%	0.52x
AMGEN INC.	33,42 Mrd	12,24%	44,96%	177,29%	11,36%	2.33x
GILEAD SCIENCES, INC.	28,75 Mrd	1,67%	29,63%	27,6%	9,57%	1.48x
PFIZER INC.	63,63 Mrd	12,62%	34,24%	19,99%	8,05%	1.52x
SANOFI	42,53 Mrd	13,98%	27,61%	11,75%	4,43%	0.68x
BRISTOL-MYERS SQUIBB COMPANY	48,3 Mrd	-18,53%	10,77%	10,23%	-9,53%	6.49x
VERTEX PHARMACEUTICALS INCORPORATED	11,02 Mrd	-4,86%	6,31%	0,65%	0,49%	-6.77x
GSK PLC	39,28 Mrd	8,21%	29,16%	48,09%	10,97%	1.22x
CHUGAI PHARMACEUTICAL CO., LTD.	7,45 Mrd	33,09%	46,3%	22%	18,71%	-1.74x
JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD	3,83 Mrd	22,64%	26,77%	14,73%	13,49%	-2.98x
TAKEDA PHARMACEUTICAL COMPANY LIMITED	30,6 Mrd	2,36%	7,48%	1,5%	1,19%	3.6x
BAYER AG	48,25 Mrd	-5,48%	11,66%	15,32%	-2,25%	3.2x
Media	43,38 Mrd	12,43%	29,58%	50,98%	10,3%	0,96x
Media ponderata per Capi.	52,06 Mrd	16,32%	32,87%	70,56%	13,25%	1,18x